TY - JOUR
T1 - Concise Review
T2 - Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine
AU - Samsonraj, Rebekah M.
AU - Raghunath, Michael
AU - Nurcombe, Victor
AU - Hui, James H.
AU - van Wijnen, Andre J.
AU - Cool, Simon M.
N1 - Funding Information:
This study was supported by funding from NUS Research Scholarship (to R.M.S.), NMRC (to S.M.C., J.H.H., M.R., and V.N.), A*STAR (to S.M.C. and V.N.), NIH (AR049069 to AJ.v.W.), the Mayo Clinic Center of Regenerative Medicine (to R.M.S.), and our generous benefactors William and Karen Eby. We appreciate our institutional colleagues in Singapore and Minnesota for stimulating discussions, including Profs. Hee Kit Wong (NUH), James Goh (NUS), and Eng Hin Lee (NUH), as well as Allan Dietz and Amel Dudakovic (Mayo Clinic).
Publisher Copyright:
© 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
PY - 2017/12
Y1 - 2017/12
N2 - Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy. Stem Cells Translational Medicine 2017;6:2173–2185.
AB - Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy. Stem Cells Translational Medicine 2017;6:2173–2185.
KW - Bone marrow
KW - Characterization
KW - Mesenchymal stem/stromal cells
KW - Regenerative medicine
KW - Release criteria
UR - http://www.scopus.com/inward/record.url?scp=85035065066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035065066&partnerID=8YFLogxK
U2 - 10.1002/sctm.17-0129
DO - 10.1002/sctm.17-0129
M3 - Review article
C2 - 29076267
AN - SCOPUS:85035065066
SN - 2157-6564
VL - 6
SP - 2173
EP - 2185
JO - Stem Cells Translational Medicine
JF - Stem Cells Translational Medicine
IS - 12
ER -